| 16.49 0.41 (2.55%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 20.15 | 1-year : | 21.6 |
| Resists | First : | 17.25 | Second : | 18.5 |
| Pivot price | 16.07 |
|||
| Supports | First : | 15.23 | Second : | 12.67 |
| MAs | MA(5) : | 16.45 |
MA(20) : | 16.31 |
| MA(100) : | 19.34 |
MA(250) : | 16.37 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 48.4 |
D(3) : | 47 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 26.18 | Low : | 8.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DBVT ] has closed below upper band by 29.0%. Bollinger Bands are 39.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.38 - 16.49 | 16.49 - 16.56 |
| Low: | 15.76 - 15.89 | 15.89 - 15.98 |
| Close: | 15.91 - 16.1 | 16.1 - 16.23 |
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Mon, 06 Jul 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewswire
Mon, 06 Jul 2026
DBV Technologies posts half-year liquidity contract figures - Stock Titan
Tue, 30 Jun 2026
DBVT, DBV Technologies Updates Biologics License Application Pro - GuruFocus
Tue, 30 Jun 2026
Optimism Surrounding DBV Technologies (DBVT) Despite Submission Delay - GuruFocus
Mon, 29 Jun 2026
DBV Technologies to file VIASKIN Peanut Patch BLA in Q3 2026 after FDA feedback - TradingView
Mon, 29 Jun 2026
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 3.525e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1,800 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6516e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 311.1 % |
| Return on Equity (ttm) | -66.4 % |
| Qtrly Rev. Growth | 5.74e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -151 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.03 |
| Dividend | 0 |
| Forward Dividend | 1.42e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|